NEW YORK, Aug 20 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX)
International VRX.TO Chief Executive J. Michael Pearson (LONDON:PSON) said
Thursday on CNBC the company had been in talks to buy female
libido drug company Sprout Pharmaceuticals for about three weeks
prior to signing the $1 billion deal.
Asked if the company had run an official sale process with
multiple bidders, Sprout CEO Cindy Whitehead said the company
had received "a lot of interest" following a positive
recommendation from the U.S. Food and Drug Administration's
advisory committee.
The FDA approved the treatment on Tuesday.